Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Related Articles
Fierce Medtech’s 2022 Fierce 15
Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of…March 20, 2023
Trial demonstrates early AI-guided detection of heart disease in routine practice
EurekAlert: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early…April 18, 2021
AI specialists ink deal with Pfizer to target cardiac amyloidosis
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…December 20, 2022
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…July 12, 2022